Background: Cadmium is a human lung carcinogen, and recent evidence suggests it may play a role in hormone-related cancers because of its estrogenic activity. Case-control studies consistently show higher cadmium concentrations in urine from women diagnosed with breast cancer compared with control women. Our aim was to investigate the association between urinary cadmium and breast cancer in a prospective design. Methods: We conducted a case-cohort study using the population-based Danish Diet Cancer and Health Cohort. Women age 50 to 64 years were recruited in 1993-1997 and provided urine for analysis. We identified 900 incident case patients in the Danish Cancer Registry and compared with 898 individuals in a subcohort. Urine samples collected at enrollment into the cohort were analyzed for cadmium and creatinine. We estimated incidence rate ratios (IRRs) for breast cancer in Cox proportional hazards models with age as time axis and calculated 95% confidence intervals (CIs). Results: The linear analysis showed no association between urinary cadmium and risk for breast cancer (IRR ¼ 1.00, 95% CI ¼ 0.81 to 1.24 per ng Cd/mL urine). The categorical analyses showed a slightly higher risk for breast cancer for the second (IRR ¼ 1.10, 95% CI ¼ 0.86 to 1.42) and third (IRR ¼ 1.14, 95% CI ¼ 0.83 to 1.55) exposure tertiles compared with the lowest tertile. Results were similar in analyses of breast cancer subtypes defined by estrogen and progesterone receptor status and by histology, and analyses stratified by years from baseline to diagnosis. Conclusions: This large prospective study showed no association between urinary concentration of cadmium and subsequent risk for development of postmenopausal breast cancer.
with oxidative stress, inflammation, DNA damage, altered DNA repair, and depressed apoptosis (2, 9, 10) . More recently, concern has been raised that chronic exposure of the general population to low levels of cadmium can increase the risk for hormonerelated cancers in general and breast cancer in particular. Mechanistic support for this concern comes from studies exhibiting estrogen-like behavior of cadmium such as proliferation of breast cancer cells (11) (12) (13) , increased expression of estrogen-regulated genes (12, 14) and activation of the estrogen receptor (ER)-a (12, 13, 15, 16) . The combination of carcinogenic and estrogenic activities raises concern that cadmium may contribute to the development of breast cancer and other hormone-related cancers.
Case-control studies consistently show higher cadmium concentrations in urine from women diagnosed with breast cancer compared with control women (17) (18) (19) (20) (21) , whereas most (22) (23) (24) (25) , but not all (26) , cohort studies found no increased risk for incident breast cancer among cohort participants with higher estimated intake of cadmium from dietary sources. Only two studies have assessed long-term exposure to cadmium by measurements in urine samples taken before the health endpoint (27, 28) , which minimizes the risk for reverse causation, although both studies used mortality as the endpoint. Neither of these two studies showed statistically significant associations between urinary cadmium and breast cancer mortality, but they were limited by few breast cancer case patients Adams: 42 case patients Garcia-Esquinas: 25 case patients.
It was the aim of the present study to investigate an association between cadmium measured in prospectively sampled urine and subsequent risk for development of breast cancer among women in the Danish Diet Cancer and Health (DCH) cohort.
Methods

Study Population
A total of 29 875 women were enrolled in the DCH cohort study during 1993-1997 (29) . Inclusion criteria were age (50-64 years), birthplace (Denmark), residence in the Copenhagen or Aarhus area, and no previous cancer diagnosis in the Danish Cancer Registry. For this study, we excluded 338 women with a cancer diagnosis before baseline, one woman with an unknown date of cancer diagnosis, and 157 with no urine sample at baseline. The study base, thus, was comprised of 29 379 women. The current study was accepted by the research ethics committee for Copenhagen and Frederiksberg. Written informed consent was obtained from all participants at enrollment into the cohort.
Incident cancer case patients among cohort members were identified in the Danish Cancer Registry, which contains accurate and virtually complete data on cancer incidence in Denmark (30) . Breast cancer case patients were identified using code C50 of the 10th version of the International Classification of Diseases. Information on estrogen receptor status, progesterone receptor status, and histology type of breast cancer case patients was obtained from The Danish Breast Cancer Cooperative Group (31) .
Information on vital status and emigration was obtained from the Central Population Registry. At enrollment, participants completed questionnaires about, among other factors, diet, lifestyle, health, and reproductive history. Anthropometric measures were taken by clinic staff, and urine and other biological samples were collected and stored at À180 C.
Selection of Breast Cancer case patients and Subcohort members
Among the study base of 29 379 women, we randomly selected 900 out of 1121 eligible breast cancer case patients and a comparison group of 898 women among the eligible cohort members. Both for case patients and the comparison group, eligible were those who were postmenopausal at baseline, who had information available on all predefined potential confounders and effect modifiers, who were living in Denmark at four years after enrollment, and who did not have any cancer diagnosis (except nonmelanoma skin cancer) during the first four years after enrollment. Undetected cancers can develop for several years and might influence biomarker levels (17) . Thus, we decided a priori to exclude those diagnosed within four years of urine sampling. The comparison group, ie, the subcohort, was selected according to the principle of a case-cohort design (32) . Among the subcohort members, 34 were also case patients. The sample size was selected to provide at least 80% power (twosided a ¼ .05) to detect effect sizes as reported in case-control studies (33) .
Assessment of Urinary Cadmium Levels
Spot urine samples given at time of clinic visit were analyzed at Research Triangle Institute International's Analytical Science Laboratory (Research Triangle Park, NC). To account for potential variation between batches, a similar number of case patient and subcohort member urine samples were randomly distributed and processed with each batch. Analytical batches were organized and shipped on dry ice to RTI in blinded fashion. Briefly, an X-series II quadrupole ICP-MS (Thermo, Waltham, MA) was used for determination of cadmium in urine, along with a suite of additional metals (antimony, barium, beryllium, cesium, cobalt, lead, molybdenum, platinum, thallium, tin, tungsten, uranium, and zinc), with special emphasis placed on mitigating the molybdenum MoO polyatomic interference (34) . Urinary creatinine concentrations were quantified using a Caymen Chemicals Creatinine Assay Kit No. 500701 (Ann Arbor, MI) with UV-VIS measurement at 500 nm employing a Beckman Coulter DU800 UV/VIS Spectrometer (Beckman Instruments Inc., Brea, CA). For a detailed discussion of the sample preparation, analysis, and extensive quality control procedures employed for this investigation, please see the Supplementary Materials (available online).
The limit of detection (LOD) for cadmium (0.03 mg/L) was calculated using the Student's t test value for approximately 150 method blanks. Batch-specific limits of quantitation (LOQ) were conservatively defined as the lowest acceptable calibration standard on each analysis day and averaged 0.125 mg/L. Average recovery of National Institute of Standards and Technology (NIST; Gaithersburg, MD) standard reference material (SRM 2668, Toxic Elements in Frozen Human Urine) aliquots with a molybdenum background was 90.2% across all batches. Random incurred retesting of 5% of the samples showed a Pearson correlation r of 0.90 with initial measurements.
For statistical analyses, cadmium concentration below the LOD (n ¼ 23) was given the value LOD/ͱ2 (35); concentrations between the LOD and the LOQ (n ¼ 430) were quantified, although with a higher uncertainty, and this value was used in the statistical analyses (36) .
Potential Confounders
Potential confounders were defined a priori based on knowledge about risk factors for breast cancer and availability and included age at first birth, number of births, hormone replacement therapy (HRT) status, years of HRT use, educational level, height, weight, alcohol intake, and physical activity.
Statistical Analyses
Data were sampled according to the case-cohort design, and the unweighted case-cohort approach was used for analyses (32) . We used Cox proportional hazards models with age as the underlying time axis; we interpret the hazard ratios as incidence rate ratios (IRRs) (37) . Follow-up started at four years after enrollment until a breast cancer diagnosis or censoring. Censoring occurred at a diagnosis of any cancer (except for nonmelanoma skin cancer), emigration, death, or December 31, 2011, whichever came first. There was no loss to follow up. We calculated two-sided 95% confidence intervals and P values based on robust estimates of the variance-covariance matrix (38) and Wald's test statistic for regression parameters in Cox regression models using the phreg procedure with option covsandwich (aggregate) of the statistical software SAS 9.3 (38) . A P value of less than .05 was considered statistically significant.
We evaluated if the association between cadmium and cancer risk was linear using linear splines with both three and nine boundaries, placed at the quartiles and deciles, respectively, among case patients (39) . We found no statistically significant deviations from linearity (data not shown). We evaluated the proportional hazards assumption for the full model by using the global chi-squared test for all variables at once, each based on a correlation test between the scaled Schoenfeld residuals and the rank order of the event time. We used the function cox.zph in the statistical software R. No deviation from the assumption was detected (P ¼ .13).
We estimated IRRs both as a linear function expressed per 1 ng/mL increase in urinary cadmium levels and for categories of exposure using tertiles of cadmium concentration in the subcohort to define the exposure groups. Results are presented with and without adjustment for potential confounders. We adjusted for creatinine concentration of each urine sample by including this concentration as a covariate (linear) in each Cox model (40).
We examined if educational level, smoking status, HRT use, and dietary intake of zinc and iron modified the association between urinary cadmium and risk for breast cancer using stratified analyses. We added an interaction term to the model and tested for interaction using Wald test.
Associations with urinary cadmium were also investigated separately for subtypes of breast cancer defined by estrogen and progesterone receptor status, and histology (ductal and lobular). Further, we separately investigated associations for breast cancer diagnosed four to seven years, eight to 11 years, and 12 to 18 years after enrollment.
We undertook a number of analyses to test the sensitivity of our results to correction strategies for levels of creatinine, logtransformation of cadmium levels, alternative cut-off points for categories of urinary cadmium, and exclusion of participants reporting diabetes at baseline, using data on smoking, HRT, weight from five years after enrollment, further adjustment for batch number of the laboratory analyses, tobacco smoking, and age at menarche. We present some of these results in the Supplementary Methods (available online).
Results
Compared with the subcohort members, case patients had a higher educational level, were more frequently HRT users, and had slightly fewer children; but case patients and subcohort members were similar for all other variables shown in Table 1 , including smoking status and urinary cadmium levels. Creatinine levels were similar in smokers (mean ¼ 705, median ¼ 556 mg creatinine/L urine) and nonsmokers (mean ¼ 700, median ¼ 544 mg creatinine/L urine).
The linear analysis showed no association between urinary cadmium and risk for breast cancer (IRR ¼ 1.00, 95% CI ¼ 0.81 to 1.24 per ng Cd/mL urine) ( Table 2 ). The categorical analyses demonstrated a slightly higher risk for breast cancer for the second-(IRR ¼ 1.10, 95% CI ¼ 0.86 to 1.42) and third (IRR ¼ 1.14, 95% CI ¼ 0.83 to 1.55)-exposure tertiles compared with the lowest tertile. The results from linear analyses showed only small differences in associations between urinary cadmium and risk for breast cancer subtypes defined by estrogen and progesterone receptor status and by histology (Table 3) , whereas the categorical analyses showed higher risk for estrogen receptor-negative breast cancer in association with the upper exposure tertile (Supplementary Table 1 , available online). Analyses stratified by years from baseline to diagnosis did not show marked differences. The 95% CIs of all subresults widely overlapped (Table 3) .
There was no statistically significant interaction between urinary Cd (continuous) and educational level, HRT use, zinc intake, iron intake, or urine sampling time of day, whereas there was a statistically significant (P ¼ .04) interaction with smoking, showing a higher risk in association with urinary cadmium among current smokers and a lower risk among never and former smokers (Table 4 ). This result was virtually unaffected by additional adjustment for smoking intensity and duration (Supplementary Table 2 , available online). Similar interaction analyses based on urinary cadmium in categories showed similar tendencies, but the interaction with smoking was not statistically significant (P ¼ .20), whereas that with HRT reached statistical significance; the breast cancer rate was about double in the third tertile compared with the first tertile among former HRT users but similar among never and present HRT users (Supplementary Table 3 , available online).
Sensitivity analyses confirmed the absence of a statistically significant association between urinary cadmium and risk for breast cancer. These analyses included use of creatininecorrected urinary cadmium instead of statistical adjustment for creatinine (Supplementary Table 4 , available online) using logtransformed cadmium levels (data not shown), using alternative cut-off points for categories of urinary cadmium (Supplementary Table 5 , available online), using information on smoking, HRT, and weight obtained five years after enrollment (Supplementary Tables 6 and 7 , available online), excluding participants reporting diabetes at enrollment (Supplementary Table 8 , available online), with further adjustment for smoking (Supplementary Table 9 , available online), batch number of the laboratory analyses, and age at menarche (data not shown).
Discussion
This study showed no statistically significant association between risk for breast cancer and cadmium levels in urine sampled at least four years before the date of breast cancer diagnosis. The results showed interactions such that higher cadmium levels were associated with higher risk for breast cancer among current smokers and former HRT users.
Our study combines the advantages of the prospective cohort design and the use of urine samples for exposure assessment. A strength of this work was our focus on high-quality urinary cadmium measurement. Collection materials were tested prior to use to ensure minimal background cadmium concentrations, a rigorous quality control regimen shows a high degree of replicability, and the vast majority of samples showed ARTICLE cadmium concentrations above the limit of detection. Even with the emphasis on reliable measurement, it is not guaranteed that the presence of the biomarker accurately reflects historical exposure. Recent reports highlight co-excretion of cadmium and proteins in the urine (41, 42) , which may explain why urinary cadmium has been associated with cardiovascular or bone diseases, which are characterized by increased excretion of proteinuria (43) . Hence, some diseases might affect the MET ¼ metabolic equivalent; T1 ¼ first tertile; T2 ¼ second tertile; T3 ¼ third tertile; U-Cd ¼ urinary cadmium. †As crude analysis plus further adjusted for educational level (<8 y, 8-10 y, >10 y), number of births (0, 1-2, 3-6), age at first birth (ever given birth: yes/no; years, continuous), HRT status (never, former, current), HRT use (years, continuous), height (cm, continuous), weight (kg, continuous), physical activity (MET score, continuous) and alcohol intake (abstainer: yes/no; intake in g/d, continuous). ‡The IRRs are given per 1 ng Cd/mL urine change in concentration; eg, the IRR of 0.95 means that a 1 ng Cd/mL urine higher concentration of urinary cadmium is associated with a 5% lower breast cancer rate (95% CI from 23% lower rate to 18% higher rate). 1 ng Cd/mL corresponds to the difference between the 10th and 90th percentile in the subcohort. §Divided into tertiles based on distribution of cadmium in the subcohort. *Life-long average for smoking periods among current and former smokers. HRT ¼ hormone replacement therapy; MET ¼ metabolic equivalent. †Among current and former smokers. ‡Among ever users who reported use for at least one year. §Among those having given birth. kAmong drinkers. ¶Sum of intake from diet and supplement. Calculated from a food frequency questionnaire filled in by participants at baseline.
ARTICLE
urinary cadmium biomarker level, and if this also applies for breast cancer it could explain why urinary cadmium has been associated with breast cancer in case-control studies, where urine is sampled after the breast cancer diagnosis. Our cohort design with inclusion of only first primary breast cancer cases that occurred four or more years after urine sampling (enrollment) minimized the risk for such potential reverse causation resulting from a preclinical breast cancer affecting the urinary MET ¼ metabolic equivalent. †As crude analysis plus further adjusted for educational level (<8 y, 8-10 y, >10 y), number of births (0, 1-2, 3-6), age at first birth (ever given birth: yes/no; years, continous), HRT status (never, former, current), HRT use (years, continuous), height (cm, continuous), weight (kg, continous), physical activity (MET score, continuous), and alcohol intake (abstainer: yes/no; intake in g/d, continuous). *Incidence rate ratios are estimated in continuous, linear analyses per increase in cadmium level of 1 ng Cd/mL urine. CI ¼ confidence interval; HRT ¼ hormone replacement therapy; IRR ¼ incidence rate ratio; MET ¼ metabolic equivalent; U-Cd ¼ urinary cadmium. †Adjusted for creatinine level (mg creatinine/L urine), educational level (<8 y, 8-10 y, >10 y), number of births (0, 1-2, 3-6), age at first birth (ever given birth: yes/no; years, continuous), HRT status (never, former, current), HRT use (years, continuous), height (cm, continuous), weight (kg, continuous), physical activity (MET score, continuous), and alcohol intake (abstainer: yes/no; intake in g/d, continuous). The IRRs express the association between U-Cd and risk for breast cancer within each stratum (eg, among present HRT users) and cannot be interpreted in terms of differences in risk between the strata, such as present vs never HRT users. ‡P value (two-sided test) for interaction.
cadmium levels. Further, the cohort design minimized risk for selection and recall bias, which might hamper case-control studies.
Other advantages of our study include the large sample size, the investigation of associations between urinary cadmium and risk for subtypes of breast cancer, and interactions with other factors such as smoking and HRT. Further, we had the opportunity to use the virtually complete and reliable nationwide Danish registries. Each Danish citizen has a unique personal identification number, which can be used for linkage with the registers for information about, eg, vital status (44) and incident cancer diagnoses (30) . The use of incidence rather than mortality data is also an advantage to our approach, not least for studies of breast cancer because of a relatively favorable prognosis for survival after a breast cancer diagnosis.
A potential weakness of our study was our inability to control for maternal breast cancer, although we adjusted for many potential confounders and did not see changes in the results. A second potential weakness is our use of a single urine sample for the exposure assessment. Such single samples are often plagued by temporal variability in a biomarker for exposure. In two recent studies, however, creatinine-adjusted urine cadmium levels have demonstrated high intra-class correlation (ICC) in spot urine samples across a week (ICC ¼ 0.70) (45), six months (ICC ¼ 0.78) (46) , or in first morning voids across a year (ICC ¼ 0.72) (47) . Findings of limited intra-individual variability help justify our use of single spot urine samples for estimating long-term exposure. Information on potential confounders was collected at enrollment, and smoking habits, use of HRT, and weight might change during the follow-up period. However, we obtained almost identical results when using data obtained at enrollment and five years after enrollment. Our study design implied at least four years from urine sampling to diagnosis to minimize the risk for reverse causation. A consequence of this design is that our results should be interpreted as related to long-term exposure rather than to more recent short-term exposure to cadmium.
The lack of association between urinary cadmium levels and risk for breast cancer in our study is in contrast with previous case-control studies using urine for exposure assessment, which consistently reported associations between cadmium and risk for breast cancer (17) (18) (19) (20) (21) , whereas previous cohort studies using estimates of dietary cadmium intake generally reported no association (22) (23) (24) (25) . A potential explanation for these differences may be the use of urine for the exposure assessment in case-control studies and estimation of dietary cadmium intake from food frequency questionnaire data in the previous cohort studies; urinary cadmium concentration is considered a valid measure for long-term body burden of cadmium, whereas the calculation of dietary cadmium intake may be a less reliable measure (48) . This is the first cohort study that has evaluated breast cancer risk using the gold standard measure of urine. The different picture derived from case-control studies and this cohort study may result from the potential for bias inherent in the case-control design. Altogether, we cannot identify obvious methodological drawbacks of this first cohort study of urinary cadmium and risk of incident breast cancer, which could explain our null finding in the main analyses.
We also found that higher cadmium levels were associated with higher risk for breast cancer among smokers but lower risk among nonsmokers. This result must be treated with caution because tobacco smoking is a major source of cadmium exposure; smokers tend to have higher concentrations of urinary cadmium than never smokers (49, 50) . Given that smoking presents a risk for breast cancer (51) , it is difficult to know whether the increased risk in smokers reflects a cadmiumspecific risk or an increased exposure to other constituents of tobacco smoke. We cannot provide an explanation for the lower risks associated with cadmium among never and former smokers or for the higher risk among former HRT users but not among never or present HRT users. Neither can we explain the higher risk for estrogen receptor-negative breast cancer in association with the higher exposure categories. These results may be because of chance and require confirmation.
The urinary cadmium levels reported here are in the range expected for healthy non-occupationally exposed Western populations (33, 45, 47, 52) . These results should be generalizable to these populations, although not necessarily to Asian populations, where the general population often has higher urinary cadmium levels (53, 54) . Our results are only generalizable to postmenopausal women. In conclusion, this large prospective study showed no association between urinary concentration of cadmium and subsequent risk for development of breast cancer.
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